Abstract:Case 1, a 63-year-old female patient presented with blisters and bullae arising in erythema all over the body with itching for 2 months. Two years ago, the patient underwent peri-intestinal lymph node dissection for the treatment of malignant melanoma of the rectum and anal canal, and received intravenous injection of toripalimab for preventive treatment for 1 year, and generalized skin lesions occurred 2 weeks after drug withdrawal. Direct immunofluorescence testing of erythema on the upper extremities showed that immunoglobulin G (IgG) was deposited along the basement membrane zone; salt-split indirect immunofluorescence testing of a serum sample showed liner deposition of IgG in the epidermis. Enzyme-linked immunosorbent assay (ELISA) revealed that the serum level of anti-BP180 antibodies was over 200 U/ml. The patient was diagnosed with bullous pemphigoid, but it was doubtful whether the disease was caused by PD-1 inhibitor toripalimab or not. Then, the patient received oral minocycline at a dose of 200 mg/d and prednisolone acetate at a dose of 20 mg/d, and topically applied halometasone cream all over the body. After half-a-month treatment, the blisters crusted over and the erythema darkened in color. Case 2, a 36-year-old female patient presented with generalized blisters and itching for more than 3 months. The skin lesions manifested as tense blisters, bullae, bloody bullae and crusts on the edematous erythema. The patient had a 3-year history of vaginal malignant melanoma, which was stage Ⅳ postoperative melanoma with local recurrence and lymph node metastasis nearby the right iliac vessels. After 2-year treatment with intravenous injection of toripalimab, generalized skin lesions occurred all over the body. Direct immunofluorescence testing of the erythema showed weakly positive staining for IgG, and linear deposition of IgG along the basement membrane zone; salt-split indirect immunofluorescence testing of a serum sample showed liner deposition of IgG in the epidermis. ELISA revealed that the serum level of anti-BP180 antibodies was over 200 U/ml. The case 2 was diagnosed with bullous pemphigoid, but it was also doubtful whether the disease was caused by PD-1 inhibitor toripalimab or not. Then, the case 2 was treated with oral doxycycline at a dose of 200 mg/d and oral prednisolone acetate at a dose of 40 mg/d. After 2-week treatment, the blisters completely crusted over and erythema darkened in color.

One Case of Bullous Pemphigoid after Eczema of Many Years

A case of systemic lupus erythematosus complicated with pemphigus vulgaris

A Case of Bullous Eosinophilic Cellulitis

A case of bullous pemphigoid with psoriasis

One case of pemphigoid nodularis

A Case of Nodular Pemphigoid

A Case of Bullous Pemphigoid after Exposure to Essential Oil in Young Women

Bullous Pemphigoid Associated with Milia, Increased Serum IgE, Autoantibodies Against Desmogleins, and Refractory Treatment in a Young Patient*

A Case of Pemphigus Herpetiformis

Widespread dermal ulcerations and bullae

Two cases of bullous pemphigoid after long-term treatment with toripalimab

016 Brunsting-Perry Pemphigoid after Remission of Previous Bullous Pemphigoid Related to Epitope Spreading from BP180 to BP230

A case of CD30+ cutaneous T-cell lymphoma accompanied with bullous pemphigoid

Case Report: The many faces of bullous pemphigoid

A Case of Bullous Systemic Lupus Erythematousus

Childhood Bullous Pemphigoid Treated by I.V. Immunoglobulin

A Case of Pemphigoid Accompany with Cutaneous Alternariosis

A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis

Bullous pemphigoid presenting as exfoliative erythroderma

Atypical Presentation of Severe Bullous Pemphigoid: A Case Report

The Treatment of Refractory Atypical Bullous Pemphigoid with Generalized Eczema and Intense Pruritus with Dupilumab